$4450
$3560
The human albumin market size is projected to reach US$ 6.98 billion by 2031 from US$ 4.68 billion in 2024. The market is expected to register a CAGR of 6.0% during 2025–2031.
Human Albumin Market Analysis
Human albumin is applied in treating trauma, burns, and hypoalbuminemia, whereas recombinant and bovine sources are increasingly adopted in biopharmaceutical production and cell culture. Rising incidences of liver and kidney diseases favor market growth. Advances in purification technology and recombinant production techniques improve product safety and efficacy. Nevertheless, dependency on plasma donations and regulatory issues act as restraints. R&D investments and strategic partnerships influence market dynamics.
Human Albumin Market Overview
Human albumin is one of the most important plasma proteins that finds widespread application in the management of liver disease, burns, shock, trauma, hypoalbuminemia, surgery, and fluid resuscitation. Increasing incidence of chronic liver disorders, expansion in surgical procedures, and growing capacity in plasma collection are key factors driving market growth. Besides, the increasing importance of human albumin in drug formulation, vaccine production, and cell culture media adds to the rising demand. Technological improvements in plasma fractionation and recombinant albumin are improving product safety and availability. However, the constrained plasma supply and strict regulations limit the growth of the market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Human Albumin Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Human Albumin Market Drivers and Opportunities
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Human Albumin Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Drivers:
Rising Demand for Plasma-Derived Therapies:
The increasing prevalence of chronic conditions such as liver disease, burns, and shock fuels demand for human albumin-based treatments in therapeutic and supportive care applications.Expansion of Biopharmaceutical Applications:
Human albumin is widely used as a stabilizing agent in biologics, vaccines, and drug delivery systems, leading to greater adoption in the biopharmaceutical industry.
Market Opportunities:
Advancements in Recombinant Human Albumin Technology:
Innovations in recombinant human albumin production offer a sustainable, non-human-derived alternative, reducing dependency on blood donations and meeting global demand with improved safety profiles.Emerging Markets Expansion:
Developing countries invest heavily in healthcare infrastructure, creating demand for human albumin-based products in diagnostics, critical care, and therapeutic treatments.
Human Albumin Market Report Segmentation Analysis
The Human Albumin market is divided into different segments to give a clearer view of how it works, its growth potential, and the latest trends. Below is the standard segmentation approach used in industry reports:
By Application:
Therapeutic Applications:
Therapeutic applications address critical medical needs such as shock, burns, and hypoalbuminemia. Their effectiveness in fluid replacement and blood volume maintenance in emergency and surgical care fuels widespread clinical use. Therapeutic applications include liver and kidney diseases, surgery, hypovolemia, hypoalbuminemia, and others.Drug Delivery:
Human Albumin’s natural ability to bind drugs increases efficacy, reduces side effects, and enables controlled release, making it a vital component in innovative biopharmaceutical formulations and treatments.Disease Diagnostics:
Human Albumin is a key biomarker for liver, kidney, and nutritional disorders. Accurate measurement supports early diagnosis, disease monitoring, and personalized treatment, increasing global demand for human albumin-based diagnostic kits and tests.Research:
Ongoing research into recombinant human albumin for drug delivery and regenerative medicine is expanding its potential applications, driving innovation and attracting global investment in product development.Others:
Human albumin’s moisturizing and skin-repair properties are useful in anti-aging and beauty products. Its natural protein benefits promote skin health, increasing demand for human albumin-based formulations in skincare and personal care sectors.
By End User:
- Hospitals and Clinics
- Pharmaceutical and Biotechnological Companies
- Research Institutes
- Diagnostic Laboratories
- Homecare Settings
- Others
By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Market Report ScopeHuman Albumin Market Share Analysis by Geography
North America dominates the human albumin market due to its advanced healthcare infrastructure, high prevalence of chronic diseases, and strong presence of key pharmaceutical companies. The region benefits from investments in research and development, enabling innovations such as recombinant human albumin. Additionally, well-established blood plasma collection systems and favorable regulatory frameworks support a steady supply of human albumin-based products, driving adoption in therapeutic and biopharmaceutical sectors.
Asia Pacific is growing at the fastest rate due to improving healthcare infrastructure and developing pharmaceutical sectors. Emerging markets in Latin America and MEA have untapped opportunities for human albumin providers to expand.
The growth of the human albumin market varies across regions due to factors such as an aging population and the increasing prevalence of mobility-related disorders. Below is a summary of market share and trends by region:
1. North America
Market Share:
Holds a significant portion of the global marketKey Drivers:
- Advanced Healthcare Infrastructure
- High Prevalence of Chronic Diseases
Trends:
Greater Adoption of Recombinant Human Albumin
2. Europe
Market Share:
Substantial market shareKey Drivers:
- Rising Demand for Plasma-Derived Therapies
- Strong Healthcare Infrastructure and Public Funding
Trends:
Shift Toward Recombinant & Animal-Free Human Albumin.
3. Asia Pacific
Market Share:
Fastest-growing region with a rising market share every yearKey Drivers:
- Growing Prevalence of Chronic Diseases
- Expanding Healthcare Infrastructure
Trends:
Expansion of Recombinant & Synthetic Human Albumin Production.
4. South and Central America
Market Share:
Growing market with steady progressKey Drivers:
- Growing Awareness and Adoption of Advanced Therapies
- Expansion of Local Biopharmaceutical Industry
Trends:
Improvement of Local Production & Plasma Fractionation.
5. Middle East and Africa
Market Share:
Although small, but growing quicklyKey Drivers:
- Rising Demand for Plasma-Derived Products
- Expansion of Diagnostic and Research Capabilities
Trends:
Rapid Growth of Recombinant Human Albumin / Cell Culture Supplements.
Human Albumin Market Players Density: Understanding Its Impact on Business Dynamics
High Market Density and Competition
Competition is strong due to the presence of established players such as CSL Ltd and Grifols SA. Niche providers contribute to the competitive landscape across regions.
This high level of competition urges companies to stand out by offering:
- Advanced Products
- Value-added services such as customization and sustainable solutions
- Competitive pricing models
- Compliance with regulatory guidelines
Opportunities and Strategic Moves
- Advancements in recombinant human albumin production offer scalable, virus-free alternatives to plasma-derived sources. Healthgen Biotechnology's rice-derived recombinant human albumin injection, approved by China's NMPA, exemplifies the potential of plant-based platforms in large-scale production.
- Human albumin's role as a stabilizer and carrier in drug formulations, particularly in nanoparticle-based systems for cancer therapies, is expanding.
- The shift toward personalized medicine is increasing the demand for customized drug formulations using human blood albumin, especially in oncology.
Major Companies operating in the Human Albumin Market are:
- CSL Ltd
- Grifols SA
- Taibang Bio Group Co. Ltd.
- Merck KGaA
- Octapharma AG
- HiMedia Laboratories Pvt Ltd
- Takeda Pharmaceutical Co Ltd
- Thermo Fisher Scientific Inc
- InVitria
- Biotest AG.
- Medxbio Pte Ltd
- Lazuline Biotech Private Limited
- Cyagen Biosciences
- Sartorius AG
- Aspira Chemical
- Lee BioSolutions
- Reliance Life Sciences Private Limited
- Kedrion SpA
- Biorbyt Ltd.
- Akron Biotech
Disclaimer: The companies listed above are not ranked in any particular order.
Other companies analyzed during the course of research:
- Albumedix Ltd. (Sartorius AG)
- Ventria Bioscience (InVitria)
- Biorbyt Ltd. (UK)
- Medxbio Pte Ltd. (Singapore)
- Akron Biotech (US)
- RayBiotech Inc. (US)
- Seracare Life Sciences Inc. (US)
- Bristol-Myers Squibb Company (US)
- Recombinant Technologies Inc. (US)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Baxter International Inc. (US)
- Hualan Bio (China)
- China Biologic Products Holdings, Inc. (China)
- Shanghai RAAS Blood Products Co., Ltd. (China)
- LFB Group (France)
- Ventria Bioscience Inc. (US)
- HiMedia Laboratories Pvt. Ltd. (India)
- Medxbio Pte. Ltd. (Singapore)
- MilliporeSigma (US)
- RayBiotech Inc. (US)
- Seracare Life Sciences Inc. (US)
- Akron Biotech (US)
- Bristol-Myers Squibb Company (US)
- Dyadic International, Inc. (US)
- Proliant Health and Biologicals (US)
- Bio Products Laboratory Ltd. (UK)
- Human Albumin Bioscience (US)
- Lazuline Bio (India)
Human Albumin Market News and Recent Developments
Healthgen Biotechnology received regulatory approval in April 2025 from China's National Medical Products Administration for its rice-derived recombinant Human Albumin injection.
This plant-based platform enables large-scale production, addressing hypoHuman Albuminemia with a sustainable and animal-free approach.Ventria Bioscience introduced a plant-based recombinant Human Albumin in June 2024.
The new plant-based recombinant Human Albumin offers a sustainable and animal-free alternative for cell culture media, regenerative medicine, and vaccine stabilization.
Human Albumin Market Report Coverage and Deliverables
The "Human Albumin Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Human Albumin Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Human Albumin Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Human Albumin Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Human Albumin Market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The human albumin market is estimated to reach US$ 6.98 billion by 2031.
The rising prevalence of chronic diseases, advancements in biotechnology, and soaring demand for biopharmaceuticals are among the noteworthy factors contributing to the market growth.
CSL Ltd, Grifols SA, Taibang Bio Group Co. Ltd., Merck KGaA, Octapharma AG, HiMedia Laboratories Pvt Ltd, Takeda Pharmaceutical Co Ltd, Thermo Fisher Scientific Inc, InVitria, Biotest AG., Medxbio Pte Ltd, Lazuline Biotech Private Limited, Cyagen Biosciences, Sartorius AG, Aspira Chemical, Lee BioSolutions, Reliance Life Sciences Private Limited, Kedrion SpA, Biorbyt Ltd., Akron Biotech are among the key players operating in the human albumin market.
North America dominated the market in 2024.
The human albumin market is estimated to register a CAGR of 6.0% during the forecast period.
The List of Companies - Human Albumin Market
- CSL Ltd
- Grifols SA
- Taibang Bio Group Co. Ltd.
- Merck KGaA
- Octapharma AG
- HiMedia Laboratories Pvt Ltd
- Takeda Pharmaceutical Co Ltd
- Thermo Fisher Scientific Inc
- InVitria, Biotest AG.
- Medxbio Pte Ltd
- Lazuline Biotech Private Limited
- Cyagen Biosciences
- Sartorius AG
- Aspira Chemical
- Lee BioSolutions
- Reliance Life Sciences Private Limited
- Kedrion SpA
- Biorbyt Ltd.
- Akron Biotech
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Human Albumin Market
Nov 2025
Human Albumin Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application [Therapeutic Applications (Liver and Kidney Diseases, Surgery, Hypovolemia and Hypoalbuminemia, and Others), Drug Delivery, Disease Diagnostics, Research, and Others], and End User (Hospitals and Clinics, Pharmaceutical and Biotechnological Companies, Research Institutes, Diagnostic Laboratories, Homecare Settings, and Others)
Nov 2025
Peritoneal Dialysis Equipment Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Peritoneal Dialysis Solution, Peritoneal Dialysis Catheters, Peritoneal Dialysis Transfer Sets, and Others), Dialysis Type (Continuous Ambulatory Peritoneal Dialysis (CAPD), and Automated Peritoneal Dialysis (APD)), End User (In-Center Dialysis Settings, and Home Care Settings), and Geography
Nov 2025
Hemodialysis Equipment Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Dialyzers, Dialysate, Access Products, and Others), End User (In-Center Dialysis Settings and Home Care Settings), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Urokinase API and Finished Dosage Forms Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Active Pharmaceutical Ingredient and Finished Dosage Forms), Manufacturing Process (Urine-derived, Cell Culture-based, and Recombinant Technology), Indication (Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), Catheter Occlusion, Myocardial Infarction (Heart Attack), Peripheral Arterial Occlusive Diseases, and Others), Distribution Channel (Hospital Pharmacies, Retail and Drug Stores, Direct Sales (API and FDF), and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
Aesthetic Fillers and Exosomes Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type [Dermal Fillers (Calcium Hydroxylapatite, Hyaluronic Acid, Collagen, Poly-L-Lactic Acid, Polymethylmethacrylate (PMMA), Fat Fillers, and Others) and Exosome-Based Aesthetic Products (Human-derived, Animal-derived, and Plant-derived)], Route of Administration [Injectable, Topical (Serum, Cream, Mask, and Others)], Application (Skin Rejuvenation, Wrinkle Reduction and Fine Line Correction, Facial Contouring, Lip Augmentation, Scar and Pigmentation, Post-procedure Recovery, Hair Restoration, and Others), End User (Hospitals, Dermatology Clinics, Medical Spas, and Others), and Geography (North America, Europe, and Middle East)
Nov 2025
Veterinary Diagnostics Products Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Kits and Reagents [ELISA Test Kits, Antibodies Test Kits, Polymerase Chain Reaction (PCR) Test Kits, Hematology Test Kits, Biochemistry Test Kits, Immunoassay Reagents, and Others]and Analyzers [Biochemistry Analyzers, Hematology Analyzers, Immunoassay Analyzers, PCR Analyzers, and Others]), Animal Type (Companion Animal [Dogs, Cats, Horses, and Others] and Livestock Animal [Cattles, Pigs, Poultry, and Others]), Application (Infectious Diseases [Rabies, Avian Influenza, Leishmania, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection, and Others] and Non-Infectious Diseases [Pneumonia, Gastritis, Bronchitis, and Others]), End User (Public Healthcare Facilities and Private Healthcare Facilities), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Nov 2025
High Potent Pharmaceuticals Product Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type [APIs (Synthetic High Potency Active Pharmaceutical Ingredients and Biotech High Potency Active Pharmaceutical Ingredients) and Finished Dosage Forms (Tablets, Capsules, Injectables, and Others)], Drug Type (Innovative Drugs and Generic Drugs), Indication (Oncology, Hormonal Disorders, Autoimmune or Immunology, Infectious Diseases, CNS Disorders, Cardiovascular Diseases, and Others), Manufacturing Type (In-House Manufacturing and Outsourced (Contract Manufacturing)), Distribution Channel (Hospital Pharmacies, Retail and Drug Stores, Online Pharmacies, and Others)
Nov 2025
Delay Condoms Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Condoms and Dental Dams), Category (Flavored and Plain), Material (Latex and Non-Latex), Distribution Channel (Supermarkets and Hypermarkets, Pharmacies and Drug Stores, Online Retails and Others), and Geography